Trails Edge Capital Partners LP Purchases New Stake in Revolution Medicines, Inc. $RVMD

Posted by Brenda Bartman on Aug 26th, 2026

Trails Edge Capital Partners LP purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 115,750 shares of the company’s stock, valued at approximately $21,677,660. Revolution Medicines makes up about 0.0% of Trails Edge Capital Partners LP’s portfolio, making the stock its 15th biggest position. Trails Edge Capital Partners LP owned approximately 0.05% of Revolution Medicines as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Meeder Advisory Services Inc. boosted its position in Revolution Medicines by 3.0% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after acquiring an additional 120 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Revolution Medicines by 1.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after buying an additional 125 shares in the last quarter. Deutsche Bank AG increased its position in shares of Revolution Medicines by 0.4% during the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock valued at $2,566,000 after purchasing an additional 130 shares during the last quarter. Contravisory Investment Management Inc. purchased a new stake in Revolution Medicines in the second quarter worth $32,000. Finally, ABS Investment Management LLC bought a new stake in Revolution Medicines in the 2nd quarter worth approximately $337,104,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the sale, the director owned 21,656 shares of the company’s stock, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Margaret A. Horn sold 60,400 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the completion of the sale, the chief operating officer directly owned 158,222 shares in the company, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 212,497 shares of company stock worth $38,206,486. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

RVMD has been the topic of a number of recent research reports. Truist Financial lifted their price objective on shares of Revolution Medicines from $231.00 to $239.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC upped their price target on shares of Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wedbush boosted their price objective on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Finally, Oppenheimer upped their price target on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $198.89.

Check Out Our Latest Analysis on RVMD

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

Positive Sentiment: FDA approval creates a commercial foothold: The FDA approved RASONQUE (daraxonrasib) for previously treated metastatic pancreatic cancer, giving Revolution Medicines its first marketed product and validating its RAS-targeted cancer strategy. The approval came unusually quickly, roughly one month after filing. RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
Positive Sentiment: Large potential market: Analysts cited peak-sales potential of approximately $11.5 billion, while clinical data indicated a meaningful survival benefit for pancreatic-cancer patients. The approved label may also expand the drug’s commercial opportunity. Revolution Medicines Won FDA Approval One Month After Filing
Positive Sentiment: Analyst targets moved higher: Guggenheim raised its price target to $275 from $240 and maintained a Buy rating. HC Wainwright reiterated Buy with a $280 target, while Wedbush and Truist also recently increased their targets. HC Wainwright expects losses to narrow in 2027 as commercialization develops. Guggenheim Raises Revolution Medicines Price Target
Neutral Sentiment: Investors are shifting from approval news to execution: Revolution Medicines chose to remain independent despite takeover interest, leaving it responsible for launching RASONQUE, building sales infrastructure and demonstrating reimbursement and adoption. Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
Negative Sentiment: Valuation and drug pricing are concerns: RVMD had already climbed more than fivefold over the past year, increasing the risk of profit-taking and disappointment if the launch does not quickly match optimistic forecasts. RASONQUE’s reported $39,800 monthly price could also create payer-access and public-pricing challenges. Revolution Med Risks Weekly Loss Despite Transformative FDA Approval
Negative Sentiment: The company remains loss-making: Revolution Medicines recently missed quarterly EPS expectations, and analysts still project significant losses in 2026 and 2027. That leaves the stock highly dependent on future RASONQUE sales and pipeline progress rather than current earnings.

Revolution Medicines Stock Down 6.0%

Shares of RVMD traded down $13.27 during trading hours on Friday, hitting $207.88. The company had a trading volume of 2,002,673 shares, compared to its average volume of 3,014,829. The firm has a fifty day moving average price of $192.43 and a 200-day moving average price of $148.17. The stock has a market capitalization of $44.56 billion, a price-to-earnings ratio of -23.57 and a beta of 1.39. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period last year, the company posted ($1.31) EPS. On average, equities research analysts forecast that Revolution Medicines, Inc. will post -8.82 EPS for the current fiscal year.

About Revolution Medicines

(Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.